Patient-centered clinical outcomes- EQ-5D-3L and net promoter score in lysosomal diseases: Data from a participating center in the National Rare Diseases Network (RARAS)MOLECULAR GENETICS AND METABOLISMIF3.52025-02-010PRE
Severe leukopenia and thrombocytopenia in an acid sphingomyelinase deficiency patient with dengue virus infection-Case reportMOLECULAR GENETICS AND METABOLISMIF3.52025-02-010PRE
Maple syrup urine disease diagnosis in Brazilian patients by massive parallel sequencing通过大规模并行测序对巴西患者的枫糖浆尿液疾病进行诊断MOLECULAR GENETICS AND METABOLISMIF3.52024-09-010PRE
A phase 2 clinical study in Niemann-Pick disease type C and GM2 gangliosidosis patients (RAINBOW)MOLECULAR GENETICS AND METABOLISMIF3.52024-02-010PRE
Time-driven activity-based costing (TDABC) of current clinical practice for mucopolysaccharidosis type II patients assisted at one institution of the Brazilian Public Healthcare System: Data from JAV-RARAS StudyMOLECULAR GENETICS AND METABOLISMIF3.52024-02-010PRE
Prevalence of migalastat-amenable mutations in patients with Fabry disease from Brazil, Argentina and ColombiaMOLECULAR GENETICS AND METABOLISMIF3.52024-02-010PRE
Hypersensitivity reactions and enzyme replacement therapy: Outcomes and safety of rapid desensitization in 5132 infusionsMOLECULAR GENETICS AND METABOLISMIF3.52024-02-010PRE
Hypophosphatemic osteomalacia induced by intravenous iron therapy: a case reportJOINT BONE SPINEIF4.32023-09-011PRE
Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry communityMOLECULAR GENETICS AND METABOLISMIF3.52023-07-0114OAAI
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry RegistryMOLECULAR GENETICS AND METABOLISMIF3.52023-02-0112OAAI
disease progression after enzyme replacement therapy interruption in a patient with cholesteryl ester storage disorderMOLECULAR GENETICS AND METABOLISMIF3.52023-02-010PRE
Functional characterization of novel variants found in patients with suspected Fabry diseaseCLINICA CHIMICA ACTAIF2.92022-09-012OAAI
Burden of phenylketonuria in Latin American patients: a systematic review and meta-analysis of observational studiesORPHANET JOURNAL OF RARE DISEASESIF3.52022-07-3011OAAI
Transformative effect of a Humanitarian Program for individuals affected by rare diseases: building support systems and creating local expertiseORPHANET JOURNAL OF RARE DISEASESIF3.52022-04-044OAAI
Hypersensitivity reactions and enzyme replacement therapy: Outcomes and safety of rapid desensitization in 1,008 infusionsJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICEIF6.62022-03-012OAAI
Influence of lysosomal diseases on reproductive parameters of animal modelsMOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
Long term efficacy and safety of pabinafusp-alfa (JR-141) in Hunter syndrome (MPS-II): 104-week data from the clinical trials in Japan and BrazilMOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey studyMOLECULAR GENETICS AND METABOLISMIF3.52021-05-0111OAAI
Exploration of the efficacy of pabinafusp-alfa (JR-141) on neurocognitive development in Hunter syndrome (MPS II): 52week data from clinical trials in Japan and BrazilMOLECULAR GENETICS AND METABOLISMIF3.52021-02-011PREAI
Pulmonary function and functional capacity in patients with mucopolysaccharidosisMOLECULAR GENETICS AND METABOLISMIF3.52020-02-010PREAI